Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis
A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Tolerability of Narrow Band UVB Phototherapy in Enhancing Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque-Type Psoriasis
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
California
-
San Francisco、California、美国、94118
- UCSF Psoriasis and Skin Treatment Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Nonimmunocompromised males or females 18 years of age or older.
- Must be able to read, understand, and speak basic English.
- Body Surface Area (BSA) involvement of greater than 10%.
- Psoriasis Area and Severity Index greater than 10.
- Obese defined as having a Body Mass Index greater than 30.
- Eligible for systemic therapy, particularly etanercept, and Narrow Band Ultraviolet B in the opinion of the investigator.
- Sign and date the appropriate written informed consent and Health Insurance Portability and Accountability Act authorization
- Negative urine pregnancy test within 7 days before the first dose of etanercept in all women (except those surgically sterile or at least 5 years postmenopausal).
- No evidence of active or latent tuberculosis based on a negative Purified Protein Derivative skin test. Patients with documentation of adequately treated tuberculosis may be enrolled.
- Sexually active subjects of childbearing potential must agree to use medically acceptable form of contraception during screening and throughout the study.
- Willing and able to self-administer subcutaneous injections or to have a qualified person available to administer subcutaneous injections
- Agrees to comply with protocol requirements, attend all regularly study visits and is considered to be a good study subject
- Meets concomitant medication washout requirements
Exclusion Criteria:
- Erythrodermic, pustular, or guttate psoriasis
- Evidence of skin conditions other than psoriasis that would interfere with study-related evaluations of psoriasis.
- Known sensitivity to any component of the study medications.
- Evidence of active infections such as fevers, chills, sweats, or history of untreated Lyme disease and active severe infections within 4 weeks before screening visit, or between the screening and Week 0 visits.
- Evidence of latent or active hepatitis B infection as indicated by positive HBsAg test during the screening visit.
- Personal or first degree family history of neurologic disease.
- Poorly controlled medical condition including, but not limited to, unstable cardiovascular disease, poorly controlled diabetes, recent stroke, history of recurrent infections, or any other condition for which, in the opinion of the investigator, participation in the study would place the subject at risk.
- History of any Tumor Necrosis Factor-α inhibitor use including etanercept, infliximab, and adalimumab within 4 weeks of starting study drug.
- History of non-cutaneous malignancy within the past 5 years.
- History of drug or alcohol abuse. Substance abuse must clearly be documented so those patients with a remote and minor history of drug/alcohol use will still have an opportunity to participate in the study.
- Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or willing to practice effective contraception during the study. Nursing mothers, pregnant women and women planning to become pregnant while on study are to be excluded.
- Plans to receive any live vaccines during the study.
- Evidence of photosensitivity disorder (i.e. polymorphous light eruption).
- Known photosensitivity or known sensitivity to any of the excipients or products to be administered during dosing.
- Current enrollment in another clinical study and treatment with another experimental drug or approved therapy for experimental use within 30 days prior to Week 0
- Cannot commit to all the assessments required by the protocol
- Any disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures
- Considered by the investigator, for any reason, to be an unsuitable candidate for study participation.
- Cannot or do not wish to comply with the protocol washout requirements (please see section below entitled "Washout Period Prior to Week 0).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
有源比较器:1 (Etanercept only)
Subjects will only be treated with etanercept.
This is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
No UVB will be given.
Sham UVB will not be used because the subjects are not blinded because they often know they are receiving sham UVB due to differences in light intensity and heat.
|
Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
其他名称:
|
实验性的:2 (Etanercept + nb-UVB)
Subjects will receive etanercept. This is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months. In addition, for months 3-6, subjects will receive Narrow Band Ultraviolet B phototherapy three times a week for 12 weeks in addition to the etanercept maintenance dose. The safety and efficacy of the combination therapy will be evaluated by the registered phototherapy nurses at each phototherapy visit and by the study investigator at monthly visits. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff. |
Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
其他名称:
Narrow band (310-312 nm) ultraviolet light B phototherapy 3 times a week during Weeks 12-24.
NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Psoriasis Area Severity Index. This Scale Ranges From 0-72, 0 Being no Disease, and 72 Being Most Severe. The Number of Patients Who Achieved 75% Improvement of Their Psoriasis at the End of 24 Weeks Are Indicated in the Outcomes Data Below.
大体时间:Weeks 12-24
|
Psoriasis area severity index was used to determine the number of patients in each treatment arm who had 75% improvement in their psoriasis.
This scale uses the characteristics of the psoriasis, such as body surface area, redness, thickness, and scaling, to determine the severity score.
|
Weeks 12-24
|
合作者和调查者
调查人员
- 首席研究员:John Koo, MD、UCSF Psoriasis and Skin Treatment Center, Department of Dermatology, University of California, San Francisco
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.